Abstract
ObjectiveTo characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have